Announced
Completed
Financials
Tags
Completed
Acquisition
United States
Venture Capital
Biotechnology
Cross Border
Private
Private Equity
biotechnology platform
Friendly
Minority
Synopsis
Goldman Sachs Asset Management, an investment manager, led a $150m Series B funding round in MOMA Therapeutics, an operator of a biotechnology platform, with participation from Section 32, Pavilion Capital, Invus, LifeSci Venture Partners, Third Rock Ventures, Nextech Invest, Cormorant Asset Management, Casdin Capital, Rock Springs Capital, Creacion Ventures and Alexandria Venture Investments. “This Series B gives us runway to move our precision medicines toward the clinic for patients in need. We welcome all new investors to our syndicate, including lead Goldman Sachs Asset Management, and are tremendously grateful to our existing investors for their steadfast support and commitment to MOMA’s vision and mission," Asit Parikh, MOMA CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.